2024 ASPHO Conference
The 2024 American Society of Pediatric Hematology/Oncology (ASPHO) Conference was April 3-6 in Seattle, Washington. The annual conference offers the latest basic, translational, and clinical research and recommendations via a mix of programs delivered by experts in the subspecialty.
Dr. Vadivelan shared her study on pituitary and pancreatic iron deposition in patients with SCD at the 2024 ASPHO Conference.
The study compared health care resource use and costs of pediatric patients with SCD compared with matched controls.
Delaying treatment for SAA until genetic testing for IBMFS may be detrimental in patients with negative workup and history.
Dr. Ansong-Ansongton shared what National Minority Health Month and Celebrate Diversity Month mean to him at ASPHO 2024.
Dr. Ansong-Ansongton described data on the impact of abnormal mitochondrial retention and cold in red blood cells in SCD.
Dr. Mamauag details her study on the need for factor VIII infusions in patients with tolerized hemophilia A on emicizumab.
Dr. Sharathkumar shared data from her 2024 ASPHO presentation on romiplostim in children with severe aplastic anemia and MDS.
The study evaluated transplant outcomes in pediatric patients with SCD who had a history of red blood cell alloimmunization.
A standardized, local TCD supported by central quality review was implemented effectively in resource-constrained settings.
ASPHO President Caroline Hastings, MD, offers highlights from the 2024 ASPHO conference in Seattle, WA.
Advertisement
Advertisement
